100% Quality Guarantee
PhD-Level Technical Support
Human CD79β/CD79B Recombinant Protein (C-His)
Key Features

Human CD79β/CD79B Recombinant Protein (C-His) (GXRP01553)

SKU GXRP01553
Product Type Recombinant Protein
Species Human
Expression System Mammalian cells
Tag C-His
Purity >90% as determined by SDS-PAGE.
$577 - $4,138

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheetsystem_update_altMSDS

Human CD79β/CD79B Recombinant Protein (C-His)

Human CD79β/CD79B Recombinant Protein (C-His) is a recombinant protein expressed in mammalian cells, spanning Met1-Asp159, with a C-terminal His tag. Predicted molecular weight: 19.14 kDa. Purity: >90% as determined by SDS-PAGE. Supplied lyophilized from a solution in PBS pH 7.4, 1 mM EDTA, 4% Trehalose, 1% Mannitol. Applications: ELISA, immunogen, SDS-PAGE and Western blot. B-cell antigen receptor complex-associated protein beta chain (CD79B) is a ~26 kDa protein. Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. For research use only.

Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. CD79B is the therapeutic target of polatuzumab vedotin (Polivy).

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose